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Cardiovascular Magnetic Resonance (CMR) is recognised as a valuable clinical tool which in a single scan setting can
assess ventricular volumes and function, myocardial fibrosis, iron loading, flow quantification, tissue characterisation
and myocardial perfusion imaging. The advent of CMR using extrinsic and intrinsic contrast-enhanced protocols for
tissue characterisation have dramatically changed the non-invasive work-up of patients with suspected or known
cardiomyopathy. Although the technique initially focused on the in vivo identification of myocardial necrosis through
the late gadolinium enhancement (LGE) technique, recent work highlighted the ability of CMR to provide more
detailed in vivo tissue characterisation to help establish a differential diagnosis of the underlying aetiology, to exclude
an ischaemic substrate and to provide important prognostic markers. The potential application of CMR in the clinical
approach of a patient with suspected non-ischaemic cardiomyopathy is discussed in this review.Introduction
Cardiomyopathies encompass a broad spectrum of myo-
cardial conditions which can affect the heart as a pri-
mary disease process or as part of a systemic disorder,
evolving toward heart failure or cardiovascular death.
Progress of modern molecular biology and its introduc-
tion into clinical cardiovascular medicine has considerably
changed the approach to cardiomyopathies and has led to
new classification schemes. While cardiomyopathies were
initially defined as disorders that were idiopathic, expert
panels classify cardiomyopathies now into: primary,
acquired and mixed [1]. This results from the data pub-
lished by the latest AHA (2006) and ESC (2008) classifica-
tions segregating cardiomyopathies into familial/genetic
and non-familial/non-genetic [2,3]. Both recommenda-
tions define a cardiomyopathy as ‘a myocardial disorder in
which the heart muscle is structurally and functionally ab-
normal in the absence of coronary heart disease, hyperten-
sion, valvular heart disease and congenital heart disease
sufficient to cause the observed myocardial abnormality’* Correspondence: r.mohiaddin@rbht.nhs.uk
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reproduction in any medium, provided the or[3]. Cardiomyopathies are therefore grouped into specific
morphological and functional phenotypes and sub-
classified into familial and non-familial forms.
Whilst prevalence of dilated cardiomyopathy reaches
36 cases per 100 000 population, these figures as well
as those reported for other cardiomyopathies, under-
estimate the frequency of the disorder as a number of
patients are asymptomatic until reaching advanced
stages of the disease. In addition, accurate diagnostic
and prognostic phenotyping of cardiomyopathy remains
a challenge owing to frequent overlapping features
between individual cardiomyopathies.
In the investigative workup for a suspected cardio-
myopathy, typically a considerable number of tests are
performed, ranging from the more routine and straight-
forward tests including ECG, echocardiogram, and exer-
cise treadmill, to the more invasive including coronary
angiography, electrophysiological studies, and endomyo-
cardial biopsy. It is key to identify a potentially treatable
substrate and then to risk stratify patients for treatment
including consideration of an implantable defibrillator
(ICD) or cardiac resynchronisation device.
Advances in cardiovascular magnetic resonance
(CMR) provide the potential to address all these import-
ant issues in a single scan setting complementing other
non-invasive tools and genetic testing. The cost-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recently pointing out the ability of CMR to act as a cost-
reducing gatekeeper to invasive coronary angiography in
specific clinical settings [4].
In a single 45–60 minute study, CMR can provide 3-
dimensional data on cardiac anatomy, function, tissue
characterisation, coronary and microvascular perfusion,
valvular disease in any selected plane, regardless of
patient’s habitus and without ionising radiation. The
relative safety of gadolinium agents and tissue character-
ising sequences allows for repeated imaging, follow-up,
family screening and serial risk stratification.
In this review, non-ischaemic cardiomyopathies (NICMP)
are approached from a clinical point of view outlining
the diagnostic and prognostic role of CMR as an integral
part of the clinical decision making algorithm.
Technical aspects
In the imaging workup of a suspected cardiomyopathy a
wide range of sequences are acquired following dedi-
cated protocols [5-8]. Figure 1 summarises a typical car-
diomyopathy protocol which will be modulated
according to the clinical suspicion of the underlying dis-
ease and throughout the scan on the basis of the evolv-
ing picture. Table 1 provides an overview of the
technical aspects of the main sequences and Table 2
highlights strengths and weaknesses for each of them.
Gross anatomical assessment
Dark-blood imaging using mutislice single-shot spin-
echo sequence (Half-Fourier Acquisition of Single-Shot
Turbo Spin-Echo, HASTE) in trans-axial, coronal and
sagittal planes allows a gross anatomical assessment in
under 3 min. Alternatively 10–12 s breathhold images in
each of the imaging planes using bright-blood imaging
with steady-state free precession sequence (SSFP) can
be performed.
Dynamic imaging
Dynamic long-axis and short-axis views of the heart are
then acquired using breath-hold cine-SSFP imaging.
Cine-CMR is accepted as the gold standard for accur-
ate and reproducible quantification of left and right
ventricular volumes, biventricular ejection fraction, and
left ventricular (LV) mass obtained through manual
planimetry or the use of semi-automated software [9].
Presence of normalised values for CMR dimensions
corrected for age, sex and body surface area helps to
diagnose subtle ventricular dysfunction with greater ac-
curacy [10]. However, motion or breathing artifacts in
sicker patients and irregular rhythms (atrial fibrillation
or frequent ectopics) add to the complexity of acquiring
high quality cine images, and in some cases real-time
cine imaging is performed with an acceptable reductionin resolution providing analysis of ejection fraction (EF),
volumes, and mass closely correlating with values
obtained using echocardiography and conventional mag-
netic resonance imaging [11-13].
Non-contrast Tissue characterisation
Specialised sequences allow characterisation of patho-
logical tissue without the need for a contrast agent. The
T2-weighted sequence, Short-Tau Inversion Recovery
(STIR) is a powerful sequence for imaging oedema sup-
pressing signal from flowing blood and from fat enhan-
cing sensitivity to myocardial fluid content. Long T2
relaxation times of water-bound protons are used to
generate a water-specific contrast resulting in high signal
intensity of oedematous tissue [14,15]. STIR imaging
can therefore detect acute myocyte swelling and intersti-
tial fluid accumulation [16]. Initially validated in the
ischaemic model, its use has been extended to NICMP,
particularly myocarditis, stress cardiomyopathy and trans-
plant rejection [17-20].
Pitfalls include low signal-to-noise ratio, surface coil
intensity variation, interfering bright signal from stag-
nant blood, motion artifacts and the subjective nature of
interpretation [21,22]. Some of these issues can be
addressed using direct quantification of T2 by mapping
techniques or shorter acquisition protocols with single-
shot techniques [23,24]. Hybrid sequences combining
turbo spin echo and SSFP have been proposed to elimin-
ate imperfect blood suppression [2].
T1-weighted and turbo-spin echo sequences are useful
to assess the pericardium and to look for fat infiltration.
Myocardial T2*-mapping is a unique technique, vali-
dated against in-vivo histology, allowing direct identifica-
tion and quantification of myocardial iron in vivo [25].
Imaging Fibrosis or Infiltration
Myocardial fibrosis or infiltration can be assessed follow-
ing administration of gadolinium. Gadolinium is an
extracellular agent accumulating in areas of interstitial
expansion (due to myocardial fibrosis, oedema or infil-
tration). Three phases can be assessed after gadolinium
injection: the first pass (immediate imaging at rest or
during stress), early enhancement (first 5 min) and late
enhancement (5 to 20 min after injection). First pass can
be used for perfusion imaging and is often given during
vasodilator stress to detect myocardial ischaemia. Fol-
lowing intravenous injection of gadolinium (0.1-
0.2 mmol/kg body weight), the contrast media is
followed through the LV at rest and during phar-
macologic stress to assess homogeneity of perfusion
[26,27]. Ultra-fast acquisition is essential and protocols
are usually based on gradient-echo or SSFP sequences
combined with parallel imaging acquiring three to five






Figure 1 Standard cardiomyopathy protocol. Standard cardiomyopathy protocol including HASTE, cine imaging, T2-weighted-imaging (STIR)
searching for inflammation/edema (white arrows), early gadolinium imaging to detect thrombus (black arrow) and LGE to identify fibrosis or
infiltration (diffuse LGE typical of amyloidosis).
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http://www.jcmr-online.com/content/14/1/54perfusion CMR can visualise inducible perfusion defects
occurring at the microvascular level in NICMP as cir-
cumferential areas of subendocardial hypoperfusion re-
solving on resting images.
Early gadoliuium enhancement (EGE) imaging (1–3 min
after injection) enables the detection of hypovascular
regions such as dark, unenhanced intra-cardiac thrombi,
and microvascular obstruction (post myocardial infarction).Table 1 Technical characteristics of standard CMR sequences
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1.3 1.9 40Late gadolinium enhancement (LGE) imaging (5–20 min
after injection) detects accumulation of contrast in areas of
infarction or fibrosis due to slower contrast kinetics and
greater volume of distribution in extracellular matrix.
This is performed using inversion recovery Turbo-
FLASH gradient echo or phase-sensitive inversion recov-
ery (PSIR) in identical planes to the cine images searching
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Table 2 Strengths and weaknesses of standard CMR sequences
Sequence Purpose Strengths Weaknesses
Breath hold balanced SSFP cine Global regional myocardial
function and wall thickness
High SNR (T2/T1) image contrast
gives reliable blood: myocardium
endocardial border definition
based on long T2 of blood
Sensitive to field inhomogeneity
(off- resonance banding artefact).
Unreliable appearance. ECG-mistriggering/
Poor breath hold
T2W-TSE with dark blood
preparation and fat-suppression
by STIR(short tau inversion
recovery)
Oedema, Infiltration Detection of myocardial fluid
content by longer T2 relaxation
time
Low SNR
Incomplete blood suppression at
endocardial boundary layer









Higher resolution than SPECT Incomplete myocardial coverage








High spatial resolution (compared
to CMR perfusion)






Myocardial fibrosis High T1 contrast of diseased
myocardium
Image contrast depends on inversion
time adjustment and Gad washout.




Real-time or single-shot versions
of many sequences above
As above No breath-holding Tolerates
ECG mistriggering
Coarser image resolution.
Cardiac motion during image.
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pulse delay timing. It allows for a faster acquisition
method without adjustment of inversion time and more
consistent image quality to the expense of a lower spatial
resolution [29,30]. This is of particular interest in patients
having difficulties performing breath-holds or in presence
of arrhythmias. PSIR appears as a reliable technique more
sensitive for detection of small, diffuse or sub-endocardial
lesions due to a better contrast when compared to a
standard 2-dimension (2D) or 3-dimension (3D) inversion
recovery gradient echo sequence [31,32].
Using inversion recovery sequences, focal fibrosis
is imaged as a localised area of high signal intensity.
The extent and pattern of LGE varies according to
the underlying pathological process and contributes there-
fore to establish the correct diagnosis in NICMP (Figure 2).
Presence of fibrosis in NICMP is often only identified
visually but its extent can be quantified as a percentage
of total LV mass using dedicated software [33]. All quan-
tification techniques rely on the fact that LGE makes the
scar appear bright and as such can be defined as a signal
intensity above normal myocardium with 2 standard
deviations (SDs) being advocated by official guidelines.
Other techniques are also used with 3, 4, 5 or 6 SDs,
manual quantification and the full-width half maximum
technique (FWHM) using half of the maximal signalwithin the scar as the threshold. While the officially
recommended 2-SD technique can double the LGE vol-
ume compared with manual, FWHM, and 5 or 6-SD
techniques, the FWHM technique appeared as the
most reproducible method for quantification of fibrosis
regardless of etiology (fibrosis due to myocardial infarct
or HCM) and compared to ex vivo data [33-35]. How-
ever, CMR spatial resolution limits evaluation of micro-
scopic interstitial fibrosis and LGE correlates poorly with
collagen volume calculated from endomyocardial biop-
sies [36]. A promising approach to overcome this limita-
tion relies on the use of T1 mapping [37].
T1 mapping
LGE imaging sequences delineate fibrosis by revealing a
relative difference in T1-relaxation times between areas
of scar (T1 shortened by accumulation of gadolinium)
and normal myocardium (T1 closer to normal as gado-
linium is rapidly washed out). T1-mapping techniques
work by measuring the absolute T1-relaxation time for
all areas of myocardium on a pixel by pixel basis. As the
shortening of T1 relaxation time is proportional to the
local concentration of gadolinium, this can reveal subtle
changes in T1 times due to expansion of the interstitial
space with collagen and other fibrous tissue compo-
nents. Early T1 mapping techniques were very time
CBA
D
Figure 2 Diagnostic patterns of LGE. Distribution pattern and location of LGE contributes to the differential diagnosis between a NICMP (A :
sub-epicardial fibrosis following myocarditis, B : circumferential diffuse enhancement in amyloidosis, C : patchy fibrosis in affected hypertrophied
segments in HCM) and a typical ischaemic sub-endocardial enhancement (D).
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dient echo cine sequence with a nonslice selective
inversion pulse after an R wave followed by a segmented
gradient echo acquisition was developed [38,39]. Mean
signal intensities obtained both before and at least twice
after contrast administration, were plotted against the
delay after the inversion pulse, deriving T1 values and
allowing calculation of a myocardial gadolinium contrast
partition coefficient. The MOdified Look-Locker Inver-
sion recovery pulse sequence (MOLLI sequence) is a
popular approach allowing measurement of T1 times in
a single breath hold [40,41]. A Shortened MOLLI
(ShMOLLI) sequence has also been recently tested,
using sequential inversion recovery measurements
within a single shortened breath hold [42,43].
The local concentration of gadolinium will be affected
by several factors including the amount of scar, the rate
at which gadolinium is cleared from the body but also
by the amount of extracellular fluid available in the body
for the contrast to distribute into [44]. With the know-
ledge of the patient’s haematocrit, simple kinetic
models allow these corrections to be made and a
standardised estimate of the extracellular volume
fraction, Ve, (an index of fibrosis if the extracellular
space is occupied by scar tissue) to be determined
[39,44].
While T1 mapping can accurately differentiate both
interstitial and replacement fibrosis from normal myo-
cardium, it cannot distinguish one type of fibrosis from
another [45]. To date very few studies using T1 mapping
in the clinical setting are published, but it is hoped that T1
mapping may provide quantitative assessment of diffuse
myocardial fibrosis in patients with cardiomyopathies.Flow quantification
Despite a lower temporal resolution compared to echo-
cardiography, assessment of valvular disease is achiev-
able using CMR velocity mapping with reproducible
results [46].
Deformation imaging
CMR myocardial tagging quantifies myocardial deform-
ation, contraction and relaxation in the radial, circumfer-
ential and longitudinal directions adding useful
information particularly prior to resynchronisation ther-
apy (Figure 3). This technique and its applications have
been recently reviewed [47].
A feature tracking method has recently been made
available for the post processing of routinely acquired
SSFP cines using inhomogeneities of the tissue as identi-
fiers, which are then identified by software algorithms
for analysing regional function. Following manual con-
touring of the LV endocardial border of the first cine
frame, the software automatically identifies and tracks
endocardial and epicardial myocardial boundaries through
the remaining phases of the cardiac cycle. Although the
method has been compared to echocardiographic speckle
tracking, it may be better described as ‘boundary’ tracking
when applied to CMR SSFP acquisitions. Potentially
derivable parameters include circumferential, longitudinal
and radially directed velocity, displacement, strain and
strain rate. However, some of these derived measures
even more than others require cautious interpretation
with respect to both spatial and temporal resolution of
cine images, and the design of the software. Feature track-
ing based measures of global strain of short axis cine
slices – essentially the relative change of length of the
BA
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Figure 3 Example of myocardial tagging using CSPAMM in an HCM patient (A: end diastole, B. end systole). Deformation curves are
extracted using a dedicated software (C). Courtesy of Dr Tevfik Ismael. Images were analysed with inTag (software supplied as part of a
collaboration agreement with University of Lyon, Pierre Croisille and Patrick Clarysse, Creatis).
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with corresponding global strain measured by CMR myo-
cardial tagging, with reduced values found in patients
with Duchenne muscular dystrophy compared with
volunteers and appeared as a promising technique to
detect wall motion abnormalities during Dobutamine
stress CMR [48-50]. However, studies of reproducibility
and accuracy of this potentially appealing analysis method
have yet to be published, particularly for analyses of
regional strain.
Limitations
Amongst limitations of CMR, metallic implants and
intracardiac Devices (pacemaker, ICD) represent the
only absolute contra-indication, but this will be over-
come in the near future by new generation of CMR
compatible pacing leads currently in clinical trials. Severe
claustrophobia, clinical instability and the first trimester of
pregnancy are among relative contra-indications. Even
though gadolinium contrast agents are relatively safe, their
use is restricted in chronic renal failure (GFR <30 ml/min)
due to the small but tangible risk of nephrogenic systemic
fibrosis (NSF) which is enhanced by concomitant heart fail-
ure [51]. On the basis of current available data, in patients
with severe renal failure, the first step is to determine
whether a non-gadolinium sequence is available and could
provide adequate data. If the clinical benefits of LGE-CMRoutweighs the risk of NSF and if no other imaging method
can be used to answer the clinical question, following a
joint discussion between the referring physician and the
patient, stable agents such as gadobenate dimeglumine
should be used as the lowest possible dose, avoiding repeat
scans within a short time period [52]. Amongst limitations
for the use of CMR, the most restrictive issue probably still
remains the limited distribution and availability of CMR
scanners.
Clinical aspects
Cardiomyopathy is often suspected on the basis of symp-
toms, an associated abnormal ECG and echocardiographic
findings. Following detection of ventricular hypertrophy,
dilatation (right or left ventricles) or abnormal wall motion
abnormalities after acute chest pain syndromes with
unobstructed coronaries, characteristic imaging features
on CMR greatly assist in reaching a diagnosis and provid-
ing prognostic information. The diagnostic and prognostic
abilities of CMR in these various clinical conditions are
reviewed. Detection of a hypertrophied LV highlights the
differential diagnosis between a physiologic response to
pressure overload (aortic stenosis, aortic coarctation,
hypertension) or pathological conditions such as hyper-
trophic cardiomyopathy (HCM), wall thickening due to
myocardial infiltration (amyloidosis), or a glycogen storage
disease (Fabry’s). CMR provides unique complementary
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teristic LGE findings distinguishing each entity are sum-
marised in Table 3.
Secondary LV hypertrophy
Although concentric LV hypertrophy (LVH) secondary
to systemic hypertension (HTN), aortic stenosis (AS), or
aortic coarctation is often suspected clinically and by
echocardiography, CMR assists the diagnosis and pro-
vides important prognostic information. This is of par-
ticular interest in cases with discrepancies between
clinical and imaging data such as marked hypertrophy
unexplained by severity and duration of HTN where an-
other underlying associated myocardial abnormality can
be detected.
In hypertensive hearts, CMR allows reproducible
assessment of wall thickness and LV mass with greater
accuracy compared to echocardiography which is par-
ticularly important for assessing small LV mass changes
over time as a consequence of treatment but also of
prognostic value as it represents an independent pre-
dictor of cardiac mortality [53,54]. Up to 50% of hyper-
tensive patients display LGE [55,56]. Although no typical
pattern of LGE has been described, focal non-
subendocardial distribution predominates. While no cor-
relation was found between presence of LGE and LVEF
or LV end-diastolic dimensions, patients displaying LGE
had in general greater LV mass. LGE in HTN offers new
insights in risk stratification which might help to deter-
mine those patients at risk of diastolic heart failure as
there is a known relationship between myocardial fibrosis
and diastolic heart failure and this might have an impact
upon therapeutic decision-making [57].
Similarly to hypertensive hearts, in aortic stenosis, LV
mass predicts the development of heart failure inde-
pendent of the degree of AS [58]. In addition, the
severity of AS and morphology of the valve can be deter-
mined by planimetry using stacks of cine CMR perpen-
dicular to the valve [59,60]. The severity of stenosis
(peak gradient) can be quantified by velocity mapping.
LGE is a frequent finding in adaptive LVH (prevalence
of 62% in AS) probably related to myocardial injury sec-
ondary to mismatch between LVH and blood supply,
and depends on the severity of LV remodeling [55].Table 3 Differential diagnosis of LV hypertrophy according to
HTN AS HCM
Pattern of hypertrophy Concentric Concentric Loca
Localisation of LGE Any segment Basal segments Hyp
segm







HTN states for hypertension, AS for aortic stenosis, HCM : hypertrophic cardiomyopAmount of fibrosis measured by CMR correlated well
with values of interstitial fibrosis obtained by histopatho-
logical analyses [61]. Whilst no specific pattern of LGE is
identified in AS, LGE was generally focal and observed
mainly in basal segments with a patchy distribution
affecting the subendocardium or the mid-wall [55,62].
Weidemann et al confirmed that myocardial fibrosis was
common in severe symptomatic AS and could be accur-
ately quantified by CMR but appeared irreversible fol-
lowing surgery and related to outcome [62].
Interestingly, the incidence of LGE was not related to the
severity of AS or to LVEF but rather to LV mass [55]. Re-
cently, CMR detected mid-wall myocardial fibrosis was
demonstrated as an independent predictor of mortality
in patients with moderate or severe AS providing an 8-
fold increase in all-cause mortality compared to similar
patients without LGE [63].
However, diffuse fibrosis can be difficult to identify on
standard LGE images. Myocardial signal with diffuse fi-
brosis will be nulled to highlight focal scar losing all in-
formation on background interstitial expansion. A
growing body of publications have addressed this issue
and several groups have extensively studied a way to de-
tect interstitial fibrosis, validating T1 mapping to derive
a fibrotic index [64-67] (see technical aspects’
paragraph).
Hypertrophic Cardiomyopathy
HCM represents the most common cause of sudden
cardiac death (SCD) in the young, including trained ath-
letes, and an important substrate for heart failure
disability at any age. Various genetic mutations lead
to a combination of myocyte hypertrophy, disarray
and fibrosis.
Although an abnormal ECG associated with marked
asymmetrical septal hypertrophy and a dynamic LV out-
flow tract (LVOT) obstruction is almost diagnostic, indi-
viduals harbouring a genetic defect for HCM do not
necessarily express clinical markers of their disease at all
times during life. As a result, even normal or mildly
increased LV wall thickness can be consistent with the
presence of an HCM-causing mutant gene. Coexistence
of HTN and HCM in a proportion of patients adds










or sub-epicardial or Mid-wall
Patchy Mid-wall
athy, LGE for late gadolinium enhancement.
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rather a spectrum of distribution and patterns of wall
thickening [68].
CMR offers the potential for high spatial resolution
images with excellent border definition allowing accurate
measurement of peak wall thickness and detection of
localised hypertrophy especially in the apical variant of
HCM and the basal anteroseptal wall, regions more diffi-
cult to image with echocardiography. LV apical aneur-
ysms, conferring increased risk of SCD, ventricular
arrhythmias, thrombo-embolic strokes and progressive
heart failure, can be identified in 2% of HCM patients
using CMR [69]. In addition, the degree of LVH mea-
sured by CMR independently correlated with NT-pro-
BNP values [70]. LGE, identified in up to 80% of HCM
patients, represents areas of focal interstitial expansion
due to myocardial fibrosis [71].
Typical patterns of LGE are patchy or confluent, gen-
erally confined to segments with greatest wall thickening
and at the RV-LV insertion points [68] (Figure 2C, 4A).
Aside from its diagnostic value, LGE extent appears
related to occurrence of ventricular arrhythmias at rest
and during exercise and increased risk of SCD poten-
tially contributing to risk assessment in borderline or
controversial cases benefiting from a prophylactic ICD
[72,73]. Even if the incidence estimate of LGE for
arrhythmic events appeared comparable to other trad-
itional risk factors (such as hypotensive blood pressure
response to exercise, gene mutations, family history of
SCD, septal thickness exceeding 30 mm) available data is
currently not sufficient to consider LGE as an independ-
ent risk factor for adverse prognosis [74].
CMR-detected myocardial fibrosis is associated with
increased incidence of atrial fibrillation (AF) and heart
failure, heralding advanced LV remodeling and systolic
dysfunction [34,75]. Interestingly, while HCM patients
without LGE had an excellent prognosis (100% event-
free survival at 6-year follow-up), LGE involving ≥5% of
LV mass, septal thickness ≥30 mm and AF were inde-
pendent predictors of death and ICD discharges [76].
Microvascular dysfunction induced by coronary arteriole
dysplasia or mismatch between increased LV mass and
coronary flow appears as circumferential stress perfusion
defects on CMR and may contribute to the risk attribut-
able to HCM [27] (Figure 4A).
Degree of LVOT obstruction and presence of systolic
anterior motion of the mitral valve can be quantified
using velocity flow mapping at rest and during stress
and have been correlated with more extensive hyper-
trophy, worse heart failure symptoms and unfavourable
outcome [77]. CMR can therefore provide important
clues to the differential diagnosis of secondary LVH ver-
sus HCM and offers an additional method for risk
stratification.Whilst no specific pattern of LGE has been identified
in secondary LVH due to HTN or AS, focal non-
subendocardial pattern has been described in the former
and patchy sub-endocardial or mid-wall LGE in basal LV
segments has been observed in the latter. This contrasts
with the typical pattern of LGE seen in HCM patients
affecting mainly insertion points and segments with
maximal wall thickness (Table 3).
Amyloidosis
This common cause of infiltrative cardiomyopathy is
classified as primary, secondary (reactive), hereditary,
and age-related. Myocardial involvement represents an
important prognostic marker of the disease influencing
treatment options [78]. Detection of early stages which
may respond to therapy and exclusion of other disease
mimicking amyloidosis appears crucial for patient’s
management.
Typical CMR findings include a small LV cavity size
with homogeneously thickened walls affecting inconsist-
ently also the right ventricle (RV). Bi-atrial enlargement,
as a consequence of the restrictive cardiomyopathy,
impaired long-axis function with preserved radial func-
tion until end-stages of the disease, thickened interatrial
septum and valve leaflets, pleural and pericardial effu-
sions resulting from interstitial amyloid fibrils deposition
are among the classical features. Around 55% of patients
with cardiac amyloidosis may present with asymmetrical
septal hypertrophy mimicking HCM.
Wassmuth et al, observed that accumulation of amyloid
fibrils can change T2 relaxation times and demonstrated
that myocardium appeared hypointense on T2-weighted
images in cardiac amyloidosis. In addition, a lower T2 sig-
nal intensity ratio (computed as myocardial over skeletal
muscle signal intensity) was independently associated with
shortened survival [79]. Further evaluation is however still
needed before applying it in routine practice.
While diffuse perfusion defects indicating microvascu-
lar dysfunction can be seen, the characteristic pattern of
LGE and the peculiar kinetics of gadolinium are unique
and discriminate this disease from other forms of hyper-
trophic cardiomyopathies. LGE reflects interstitial ex-
pansion by amyloid fibrils and appears as widespread,
circumferential enhancement mostly of the sub-
endocardium matching the distribution of amyloid pro-
tein on histology, giving rise to a characteristic ‘zebra’
pattern [78] (Figure 2B, 4B). This refers to the typical as-
pect seen in a 4-chamber view when sub-endocardial RV
and LV amyloid deposition gives rise to biventricular
subendocardial enhancement separated by a dark mid-
wall septum. Although the most frequent finding is glo-
bal sub-endocardial enhancement (up to 50% of
patients), mid-wall (a third of patients) and sub-
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Figure 4 Thickened myocardium. (A) HCM with asymmetrical septal hypertrophy (a, arrow) and a confluent LGE pattern matching the
hypertrophy (b, arrow). Dynamic LVOT obstruction with SAM (c: diastole, d: systole with a SAM) and circumferential sub-endocardial ischemia
in hypertrophied areas as a consequence of microvascular dysfunction are among classical features (e top: stress-induced perfusion defects,
e bottom: normalization at rest). (B) Amyloidosis with a typical circumferential diffuse enhancement (‘zebra’ pattern). (C) Anderson-Fabry
disease with concentric LV hypertrophy (a) and patchy LGE affecting the inferolateral wall (b, arrow).
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also be associated.
Faster washout of gadolinium from blood into the
total amyloid load leads to a technically challenging LGE
acquisition with the inability to adequately null myocar-
dial signal. High myocardial uptake and fast blood wash-
out result in a dark blood pool due to similar myocardial
and blood T1 values. To visualise myocardial and blood
pool gadolinium kinetics before setting an inversion time
when suspecting cardiac amyloidosis, an inversion time
scout corresponding to an inversion-time mapping se-
quence with images generated at 30 ms inversion time
increment, can be run early following contrast injection
(less than 5 minutes). LGE has a reported sensitivity andspecificity of 86% for the identification of cardiac in-
volvement in patients with systemic amyloidosis, detect-
ing early abnormalities in patients with normal LV wall
thickness, and appeared strongly related to heart failure
severity [80-82]. Additionally, gadolinium kinetics reflect-
ing cardiac amyloid burden predicted the risk of mortal-
ity providing a novel prognostic marker [83]. Abnormal
T1 intramyocardial gradient was suggested as a way to
identify patients in whom early use of intensive chemo-
therapy might be justified and appeared as a better pre-
dictor of survival than response to chemotherapy or
diastolic function in this study [83]. However, further ex-
perience with T1 intramyocardial gradient in amyloidosis
and reproduction of these results are still needed.
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This treatable cause of LV hypertrophy affects 1-2% of
middle aged patients suspected of HCM [84]. Concentric
hypertrophy as a result of tissue deposition (lysosomal
storage disease) is an early finding. However, asymmetrical
septal thickening mimicking HCM can occur. CMR can
suspect the diagnosis as the LGE pattern differs to that
seen in HCM and displays a regional distribution which is
helpful to distinguish Fabry’s disease from HCM. Almost
50% of patients have mid-wall LGE in the basal inferolat-
eral wall related to myocardial collagen scarring specific to
Fabry’s disease [85] (Figure 4C). Although the reasons for
this distribution of fibrosis are unclear, this may be the
substrate for electrical re-entry and SCD [86]. Regression
of LV hypertrophy under enzyme replacement therapy
can be accurately monitored by CMR [87]. Similarly, sig-
nificant reductions in myocardial T2-relaxation time have
been described witnessing the effects of enzyme replace-
ment therapy [88]. Further validation of this method is
still under way.
Dilated cardiomyopathy (DCM)
The term DCM is applied in the presence of LV or
biventricular dilatation and dysfunction following sys-
tematic exclusion of all obvious or detectable causes of
cardiomyopathy. In up to 50% of cases the aetiology
remains unknown, with 20-30% of familial cases attribu-
ted to known genetic abnormalities [1,89]. Myocarditis,
in the chronic stage, has been described as an underlying
aetiology of DCM inducing apoptosis through virus and
immunocyte-mediated pathogenic mechanisms.
DCM is the second most common cause of heart fail-
ure and the most frequent cause of heart transplant-
ation. In addition to providing accurate and reproducible
assessment of ventricular volumes and LVEF, the LGE
technique detects a pattern of fibrosis in DCM which is
typical mid-wall and seen in one third of cases. CMR by
detecting the pattern of fibrosis contributes significantly
to ruling out ischaemic aetiology and providing prog-
nostic information.
The specificity of the LGE pattern in ischaemic car-
diomyopathy (ICM) has been underscored by several
studies in which coronary angiography and CMR were
performed in patients with systolic dysfunction of
unknown aetiology [90].
In a large study comparing patients with a diagnosis of
DCM with unobstructed coronaries and patients with
known coronary artery disease and a group of normal
controls, three LGE patterns were reported [90]. The
ischaemic pattern, with LGE spreading from the sub-
endocardium to the epicardium, was seen in all patients
with documented coronary artery disease. In those with
unobstructed coronaries, 59% had no LGE while 28%
had mid-wall LGE predominantly in the septum(Figure 5A). What was surprising was that 13% of the
cohort displayed an ischaemic pattern presumably as a
result of transient occlusion caused by a non-obstructive,
unstable plaque or vasoconstriction (Figure 5B). Pres-
ence of an ischaemic pattern increased the risk of major
cardiac events by at least sevenfold.
Presence and transmurality of fibrosis in DCM has
been linked to increased risk of SCD and ventricular
arrhythmias independent of other markers of risk such
as reduced LVEF [91,92].
Wu et al reported an eightfold increased risk of heart
failure, ventricular arrhythmias and cardiac death in
DCM patients with LGE referred for an ICD [93].
Mechanisms contributing to fibrotic changes in DCM
include inflammation, neurohumoral changes and micro-
vascular ischaemia [94]. Limited CMR spatial resolution
allows only the detection of areas of macroscopic replace-
ment fibrosis responsible for promotion of re-entry
mechanisms causing malignant ventricular arrhythmias.
Whilst the patterns of LGE observed in DCM patients
are distinct from those seen in ICM, mid-wall but also
epicardial, diffuse and focal patterns are seen [92,93]. It
is still unclear whether various patterns represent differ-
ent aetiologies and it is likely that a subset of patients
suffered from myocarditis which developed into DCM.
Assomull et al, demonstrated recently that LGE was
highly effective in detecting the underlying aetiology of
newly diagnosed LV dysfunction and could be used as a
safe and effective gatekeeper to coronary angiography
[4]. While presence of LGE prompted further investiga-
tions with coronary angiography, absence of LGE was
combined to the analysis of magnetic resonance coron-
ary angiography to rule out major 3-vessel disease or left
main stem stenosis before ascribing a diagnosis of DCM.
Pilz et al, reported previously the role of Adenosine
stress CMR as a gatekeeper to coronary angiography
in a different patient population demonstrating the high
accuracy of CMR in detecting significant coronary artery
stenoses inducing 30% reduction in the rates of coronary
angiography [95].
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
A dilated RV of unexplained aetiology should raise the
possibility of ARVC particularly if associated with
aborted SCD from arrhythmias, often the first manifest-
ation of the disease.
This inheritable condition predominantly involving the
RV with progressive loss of myocytes and fibrofatty tis-
sue replacement can affect the LV in up to 75% of
patients. In spite of recent advances in genotyping, clin-
ical diagnosis remains challenging.
While the classic phenotype describes progression
of regional to global RV dysfunction, followed by LV
involvement and biventricular failure, recognition of
Figure 5 Pattern of fibrosis in DCM. Typical mid-wall LGE seen in DCM (A, arrows) differing from the sub-endocardial ischaemic pattern (B).
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have raised questions regarding its differentiation from
other myocardial disorders, such as DCM. Diagnosis
relies largely on the ARVC Taskforce criteria, recently
revised to include quantitative parameters for imaging
studies, improving sensitivity of detection of gene-
carriers with limited disease expression and those with
left-sided disease features [96].
These published cut-off values for RVEF and end-
diastolic volumes (Major criteria : Regional wall motion
abnormality and RV end-diastolic volume ≥110 ml/m2
for male and ≥100 ml/m2 for female or RVEF ≤40%;
Minor criteria : Regional wall motion abnormality and
RV end-diastolic volume ≥100- <110 ml/m2 for male
and ≥90- < 100 ml/m2 for female or RVEF >40% - ≤45%)
have been defined on the basis of comparison with
normal patient data.
Luijkx et al applied these modified criteria to help distin-
guish ARVC from physiological adaptation seen in athletes.
RVEF and LV/RV end-diastolic volume ratio appeared as
the most discriminant parameters in this situation [97].
CMR is therefore an integral component of the clinical
evaluation and represents the gold standard for assessing
the RV when performed in dedicated centers by experi-
enced operators, enhancing the sensitivity of diagnosis
particularly in early phases of the disease.Regional and global RV function, wall motion abnor-
malities, aneurysms or areas of thinning are best
detected by series of high temporal resolution trans-
axial cine of the RV reaching 96% sensitivity and 78%
specificity when part of a comprehensive non-invasive
work-up (Figure 6) [98].
T1-weighted spin echo images used initially to image
myocardial fat proved of limited diagnostic value since
adipose infiltration of the RV occurs also in healthy indi-
viduals and is difficult to image in the thin RV wall.
LGE as part of a dedicated protocol appears as the
most discriminating factor with a high diagnostic sensi-
tivity and specificity [98]. While RV LGE is difficult to
distinguish from myocardial fat and requires substan-
tially different inversion times compared to the LV, LV
mid-wall or sub-epicardial LGE can contribute to delin-
eate different patterns of ARVC. In the classic form,
mid-wall LGE is seen in the inferolateral and inferior
wall while the left-dominant phenotype often mid-
diagnosed as DCM, may include prominent LV mid-wall
enhancement affecting the septum with preserved RV
function [99].
Although the prognostic value of CMR is still under
investigation, LGE appears to predict inducibility of
sustained ventricular tachycardia and occurrence of RV
dysfunction [100]. However, lack of specificity of LGE
BA
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Figure 6 ARVC. Findings suggestive of ARVC include localized aneurysms in the RV outflow tract (arrows, A: diastole, B: systole), LGE of the free
wall (C, arrow) and in the left-sided form areas of mid-wall LGE at the RV-LV insertion point (D, arrow).
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teria (requiring the combination of wall motion abnor-
mality with global RV dilatation or dysfunction) may not
have improved the sensitivity of detection of ARVC des-
pite keeping high specificity [101]. This highlights the
importance of a combined diagnostic approach (clinical,
electrophysiological and imaging).
Chest pain syndromes with unobstructed coronaries
CMR provides unique diagnostic information in patients
with cardiomyopathy of unknown aetiology presenting
with troponin positive chest pain syndromes (CPS)
unexplained by significant coronary lesions [102]. In a
cohort of 130 patients, CMR contributed to reach a
diagnosis in 77% of patients presenting with CPS with
unobstructed coronaries, correcting a wrong suspected
diagnosis in 10% of patients and leading to change in
therapy in 33% [103].
Key features rely on the use of T2-weighted imaging
increasing the sensitivity and specificity of detection of
an ischaemic insult and on the typical pattern of LGE
distinguishing an ICM from an NICMP and detection of
myocarditis and Tako-tsubo [104] (Figure 5B and 7).
Myocarditis
Myocarditis occurs with a wide spectrum of clinical mani-
festations ranging from flu-like symptoms to troponin
positive CPS, severe heart failure and SCD. Endomyocar-
dial biopsy recognised as the gold standard for the diagno-
sis remains limited by insensitivity and sampling bias.
CMR can image several aspects of myocardial injury.In the acute stage of the disease, oedema following
lymphocytic infiltration and myocytolysis appears as
regions of high intensity on T2-weighted images. EGE
matching areas of T2-hyperintensity may reflects tissue
hyperemia and increased interstitial space [105].
LGE identifies inflammation and fibrosis acutely and
areas of irreversible necrosis in later stages, typically affect-
ing the sub-epicardium sparing the sub-endocardium of
the lateral wall (Figure 7A). Mid-wall LGE has also been
described in myocarditis [106]. This distribution pattern
seems specific for viral myocarditis with a relationship
between affected segment and type of virus [106]. The local-
isation of myocardial damage can guide endomyocardial bi-
opsy enhancing diagnostic accuracy. Pericardial
hyperintensity on T2-weighted images associated to peri-
cardial effusion detect associated pericarditis.
Among patients presenting with troponin positive CPS
with unobstructed coronaries, CMR was able to identify
a cause in 65% of patients with the commonest being
myocarditis [107]. In patients with unexplained cardio-
myopathy, up to 10% of patients were found to have
CMR findings of myocarditis [17]. Beside its diagnostic
value, increased LGE at 4 weeks after clinical onset has
been inversely correlated with 3-year follow-up LVEF
[108].
A large consensus group provided recommendations
on the use of CMR in patients with suspected myocar-
ditis suggesting the combination of 3 CMR criteria (‘Lake
Louise criteria’) to increase the diagnostic accuracy [18].
Authors recommend the combined use of 3 tissue mar-
kers: regional or global hypersignal intensity on T2-
e d 
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Figure 7 Acute chest pain syndromes (A) Acute viral myocarditis displaying edema on STIR images (a-b, arrows) and typical sub-
epicardial LGE (c-d, arrows). (B) Tako-tsubo with acute apical ballooning of the LV (a: diastole, b: systole displaying apical akinesia, arrows)
without LGE (c) followed by complete LV functional recovery at follow-up (d: diastole, e: systole).
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dium and skeletal muscle) and at least 1 focal lesion on
LGE with a non-ischaemic distribution. When 2 or more
of these tissue-based criteria were positive, myocarditis
could be ruled out or predicted with a diagnostic accur-
acy of 78% as compared with endomyocardial biopsy.
However, diagnostic accuracy of CMR in various clinical,
histological and immunohistochemical subgroups still
needs large multicenter trials validation [18].
Tako-tsubo cardiomyopathy
Acute but rapidly reversible LV systolic dysfunction in
absence of coronary artery disease, triggered by profound
psychological stress characterises this stress-mediated
myocardial stunning. Mid and apical LV segments akin-
esia with ballooning and compensatory hyperkinesia of
basal segments producing a dynamic obstruction is a
typical finding. RV is involved in 25% of patients.
Focal and transient transmural hyperintensity on T2-
weighted imaging reflecting oedema matching the distribu-
tion of wall motion abnormality seems to be a feature of
Tako-tsubo cardiomyopathy related to the severity of LV
systolic dysfunction [19]. Lack of perfusion defect or LGE
is typical, contrary to myocarditis and infarction [109]
(Figure 7B). However, up to 33% of patients display mid-
wall patchy LGE at 24 hours with complete resolution at
follow-up corresponding to reactive transient gadolinium
accumulation related to increased wall stress [110,111]. In
contrast to other cardiomyopathies such as myocarditis,
presence of LGE did not correlate with worse outcome.
Complete recovery of LV function at follow-up is typical.
Recently, Eitel et al analysed the CMR findings in Tako-
tsubo cardiomyopathy in a large multicenter prospective
cohort [112]. These observations highlighted the presence
of a much broader clinical profile than previously reported
with a significant percentage of men and younger and only
two-thirds of patients exposed to a preceding stressor.
CMR demonstrated a variety of ballooning patterns with
the apical one being the most frequent, followed by mid-
ventricular (17%), biventricular and basal (1%) types.
Authors identified several diagnostic criteria requiring fur-
ther validation in other cohorts combining severe LV dys-
function in a non-coronary regional distribution pattern,
myocardial oedema concordant to the regional wall mo-
tion abnormality (verified by a quantitative signal
intensity analysis), absence of LGE, increased EGE and
complete resolution after 4 weeks.
CMR features of other cardiomyopathies
Sarcoidosis
This multisystem granulomatous disease of unknown
aetiology involves the myocardium in 20-30% of cases.
Clinical myocardial involvement (5% of patients) ranges
from asymptomatic conduction abnormalities to heartfailure or fatal ventricular arrhythmias. An early diagnosis
is crucial as current therapy may effectively prevent death
from arrhythmias and cardiac failure. Endomyocardial bi-
opsy and echocardiography proved insensitive diagnostic
tools detecting mostly advanced stage of the disease.
Although results of prospective data are awaited, CMR
appears promising for the early diagnosis and for monitor-
ing treatment response, providing novel risk stratification
criteria for SCD and heart failure. T2-weighted and STIR
imaging detect localised areas of myocardial inflammation.
Cines identify areas of thinning and regional wall motion
abnormalities and LGE detects focal scarring, typically
patchy, mid-wall or sub-epicardial, frequently involving
the anteroseptal and anterolateral walls [113] (Figure 8).
Patel et al described a large spectrum of LGE patterns.
While the majority of affected myocardial segments had
non-transmural involvement, explaining normal ven-
tricular wall motion, there was a predilection for basal
and mid-ventricular septum with up to 48% of regions
displaying sub-endocardial LGE similar to coronary
artery disease LGE. However, 86% of affected patients
had also at least one region of LGE with a non-
ischaemic type pattern. Sub-endocardial LGE of the RV
side of the septum was a common finding and could be
associated with LGE of the RV free wall [114].
CMR appeared more sensitive for disease detection
compared to Thallium SPECT and gallium SPECT [115].
Recent studies demonstrated that 18 F-2-fluoro-2-
deoxyglucose positron emission tomography (FDG-PET)
was as sensitive as CMR for detection of earlier stages of
sarcoidosis [116]. A structured clinical assessment incor-
porating imaging with FDG-PET and CMR appeared more
sensitive than the established clinical criteria. Using the
widely described Japanese Ministry of Health and Welfare
criteria as a gold standard, CMR had a diagnostic sensitiv-
ity of 100% [117]. LGE appeared as twice as sensitive for
detection of cardiac sarcoidosis as current consensus cri-
teria and portended a ninefold higher rate of adverse
events including cardiac death [114]. Patients with LGE
had a higher rate of diastolic dysfunction, reduced RVEF
and evidence of non-sustained ventricular tachycardia
[118]. Interestingly, LGE may guide localisation for endo-
myocardial biopsy and monitor the efficacy of steroid ther-
apy [119]. However, LGE pattern is non-specific and the
predictive value of a negative CMR remains unknown.
LV non-compaction (LVNC)
This rare congenital disorder is characterised by a
“spongy” appearance of the LV (and the RV in <50% of
cases) resulting from an arrest in normal embryogenesis.
LVNC may be associated with neuromuscular disorders,
leading to heart failure, arrhythmias and thrombo-embolic
manifestations. Although echocardiography is considered
as the reference for the diagnosis, CMR accurately
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Figure 8 Sarcoidosis. Hilar lymphadenopathy on HASTE (A, arrows), localized edema in the lateral wall on STIR images (B, arrow) and mid-wall
LGE (C, arrow) are suggestive of sarcoidosis.
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apex and the lateral wall [120].
Hyper-trabeculation with a end-diastolic ratio of non-
compacted over compacted myocardium of 2.3 distin-
guished pathological from non-pathological conditions with
a sensitivity of 86% and specificity of 99% [120] (Figure 9).
Although a variety of morphological findings are described,
the absence of well-formed papillary muscles is a clue to
the diagnosis. Trabecular sub-endocardial, mid-wall or
transmural LGE and sub-endocardial perfusion defects sug-
gestive of areas of microvascular dysfunction have beenA
B
C
Figure 9 Left ventricular noncompaction LVNC with marked
LV apical and lateral wall trabeculations, arrows (left panel:
diastole, right panel: systole, A: mid-segment, B: apical
segment, C: 2-chamber view).reported. Dodd et al noticed a correlation between extent
of LVNC, amount of trabecular LGE and LVEF (35). Simi-
larly, Nucifora et al, suggested that presence and extent of
LGE were independently related to LVEF [121]. However,
the prognostic value of these findings has yet to be shown.Iron-overload cardiomyopathy
Heart failure due to myocardial iron overload remains
the leading cause of death in patients with transfusion-
dependant anemias. Reversibility of this condition
relies on early and intensive iron chelation. CMR has
made possible the accurate measurements of both
liver and cardiac iron in the same study detecting myo-
cardial involvement.
Anderson et al, first reported the utility of T2* imaging
to detect and quantify myocardial iron, unrelated to the
extent of liver iron deposition [25]. Myocardial T2* arises
principally from local magnetic field inhomogeneities that
are increased with greater iron deposition. Typical sub-
epicardial iron deposition in mid-septum is visualised by
acquiring a mid short-axis slice at nine separate echo
times to derive the T2* value (Figure 10). Reduced T2* re-
laxation times <10 ms found in thalassemia patients with
new onset heart failure defines severe cardiac iron over-
load and strongly relates to decreased LVEF. T2* has been
used as a predictive marker of heart failure and arrhyth-
mias but also to direct treatment and monitor chelation
therapy’s efficiency, resulting in 80% reduction in mortality
rates for this condition in the United Kingdom [122].
Carpenter et al, confirmed recently that mid-ventricular
septal iron, measured ex-vivo in human hearts from thal-
assemia patients, and using the CMR relaxation param-
eter R2* (assessed clinically as its reciprocal, T2*) were
highly representative of mean global myocardial iron val-
idating current clinical practice [123].
Interestingly, macroscopic fibrosis detected by LGE is
uncommon in thalassaemia patients despite current or
prior heart failure and across a broad spectrum of myo-
cardial iron loading [124].
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Figure 10 Myocardial iron overload. A mid-level gradient echo short-axis slice is imaged at different echo times (A: 2 ms to D: 14 ms) and
T2*value is estimated from the signal intensity decay curve (E). Typical sub-epicardial iron deposition can be seen (arrow).
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Despite significant advances in anti-rejection therapy,
acute cellular allograft rejection remains a leading cause
of early mortality among transplanted patients. The
diagnostic gold standard technique remains repeated
endomyocardial biopsy largely limited by insensitivity.
CMR can assist the detection of rejection mainly
through myocardial T2 relaxation time quantification with
sensitivities and specificities approaching 90% except for
the early peri-operative period characterised by normal
post-operative oedema [125]. A complete normalisation of
T2 relaxation times was seen following treatment of rejec-
tion. Marie et al, suggested that CMR sensitivity might
help to predict rejection in some biopsy-negative patients
[126]. Beyond the first year, transplant coronary artery dis-
ease (TCAD) is the second most common cause of death
after malignancy. Patterns and prevalence of LGE were
investigated in heart transplant patients undergoing rou-
tine coronary angiography [127]. While 50% had a non-
ischaemic pattern of LGE, 30% of event-free patients with
unobstructed coronaries had a typical infarction pattern
associated with worse LV function and higher BNP values.
LGE might therefore help earlier diagnosis of TCAD
allowing intensification of therapy in selected patients.
Data on prognostic implications are awaited.
Chagas disease
Cardiac involvement by Trypanosoma cruzi infection
occurs in 30% of seropositive patients representing a
major cause of death from heart failure in Latin America.LGE-CMR typically involves the apical and mid-
inferolateral wall in patients with advanced disease but
also in asymptomatic seropositive subjects without wall
motion abnormalities [128]. Ischaemic and non-
ischaemic LGE patterns are reported evolving toward
areas of thinning, aneurysms and LV dysfunction. Myocar-
dial fibrosis correlated inversely with LVEF and clinical
status. Preliminary data suggest a direct relationship be-
tween amount of fibrosis and patient’s prognosis [129].
Chemotherapy induced-cardiomyopathy
The most common adverse effect of chemotherapy is car-
diotoxicity affecting patient’s prognosis and quality of life
independently of the oncological issue. A wide range of
agents have been associated with cardiotoxicity, anthracy-
clines and related compounds being the most frequently
implicated.[130]. Incidence of clinical heart failure varies
from 1 to 5% and asymptomatic LV dysfunction ranges
from 5 to 20%. Toxicity can occur early (within a year) or
be delayed. Two types of cardiac toxicity have been
described: type 1 resulting in permanent damages to the
myocardium due to cell death and type 2 due to cellular
dysfunction following drug toxicity and usually reversible.
Cumulative dose, age at the time of drug exposure, con-
comitant use of other chemotherapeutic agents, chest ir-
radiation and preexisting cardiovascular disease are
among risk factors to develop chemotherapy-induced
cardiomyopathy.
While echocardiography remains the commonest imag-
ing modality used to follow-up LVEF in patients at risk of
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CMR in this setting have raised interesting issues. In a
population of patients receiving trastuzumab therapy for
breast cancer and developing LV dysfunction, authors
reported the presence of sub-epicardial LGE in the lateral
wall in all patients as a sign of myocarditis induced by
drug toxicity [131,132]. Other authors suggested that ab-
sence of LGE was associated with reversibility of LV dys-
function [133]. However, these preliminary findings still
need confirmatory studies by other groups.
Differential diagnosis of NICMP-Practical tips
An optimal nulling of the myocardium is key to LGE in-
terpretation and detection of small areas of fibrosis or
quantification of sub-endocardial scars. Although the
optimal inversion time can be set based on experience, a
single short axis slice can be acquired automatically at
different inversion times. The optimal inversion time is
then selected visually as the one nulling completely the
healthy myocardial signal. According to the underlying
suspected pathology, LGE should be acquired before 10
minutes such as in amyloidosis due to the faster washout
of gadolinium from blood pool. In cardiomyopathy
patients, gadolinium washout can also be faster, needing
an earlier acquisition to obtain optimal nulling of the
myocardium. This is thought to be related to structural
alterations of extracellular matrix associated with
reduced myocardial blood flow in DCM patients [39].
Once the optimal inversion time is chosen, it should be
adjusted throughout the scan, typically increased from
310 to 420 ms. Presence of a subtle area of LGE is con-
firmed if myocardial enhancement persists when reim-
aged in the same plane with a different orientation phase
(phase swap) ruling out an artifact. Similarly, performing
crosscuts through the suspected region of LGE (per-
forming another plane cutting the area in question) will
assure presence of fibrosis and help define its transmur-
ality within the wall. Similar acquisition techniques can
be used for STIR imaging.
When to order a CMR scan
Lack of ionising radiation, excellent spatial resolution, 3D
anatomical assessment and ability to provide tissue char-
acterisation with and without contrast are amongst advan-
tages of CMR making it a valuable and complementary
tool to other non-invasive modalities. CMR is recognised
as a class I indication for EF, volumes and mass quantifica-
tion [9]. CMR should therefore be performed to quantify
EF in patients with poor echocardiographic window and
in controversial cases where precise determination of EF
will impact upon decision regarding treatment, device im-
plantation or follow-up (i.e ICD or CRT). In these specific
cases, CMR can contribute to the decision-making process
by adding important prognostic information reflected byLGE burden as reviewed in previous sections. In addition,
CMR represents the most reproducible tool for LV mass
measurements at baseline and during follow-up under
treatment. CMR should also be an adjunct to the work-up
of all patients with suspected cardiomyopathy due to its
ability to study the RV, to detect subtle wall motion abnor-
malities or reduction in LVEF, to identify myocardial
oedema and small areas of fibrosis or scarring.
LGE CMR appears highly effective in identifying the aeti-
ology of LV dysfunction in newly diagnosed heart failure
and can be used as a safe, clinically effective and potentially
economical gatekeeper to coronary angiography in these
patients [4]. Safety of repeated imaging allows screening of
cardiomyopathy family members or athletes who experi-
enced unexplained syncope or aborted SCD. CPS with un-
obstructed coronaries represent another condition where
CMR has the unique capability of discriminating infarction
from myocarditis or tako-tsubo cardiomyopathy driving the
clinical management of these patients. To promote the
quality and impact of CMR imaging and to be able to set
international benchmarks on appropriate indications, qual-
ity and safety of CMR, a European registry, EuroCMR
registry is currently recruiting patients’ data from a large
number of participating centers [134].Comparison with other Imaging modalities
Whilst CMR offers an excellent morphological evalu-
ation through its high spatial resolution, echocardiog-
raphy excels through its unique temporal resolution,
providing a non-ionising, inexpensive bedside tool, su-
perior for haemodynamic evaluation (filling pressures,
diastolic function, restrictive physiology, valve disease).
Limitations are linked to its restricted lateral spatial
resolution, the dependency on good acoustic windows
particularly in patients with chronic lung diseases, and
the limited assessment of apical segments and the RV.
CMR remains partially limited by arrhythmias interfer-
ing with ECG triggering and poor ability to perform
breath-holds. Metallic non-CMR safe devices and severe
renal failure prevent its use.
Cardiac computed-tomography (CCT) provides a fast
and accurate 3D assessment of coronaries and myocar-
dium in a 30-second time frame even in patients with
pacing devices. However, the use of CT remains limited
by radiation, renal failure often encountered in heart
failure patients (for CT contrast agents), pregnancy and
limited assessment of late enhancement still inferior to
CMR. It can however be considered as an alternative in
patients with pacing devices.
Nuclear and CT hybrid devices are rapidly evolving to
incorporate high-speed MDCT along with positron-
emission tomography (PET) and single-photon emission
tomography (SPECT) detector systems.
Table 4 Comparison of Imaging Modalities for the evaluation of NICM
Echo CMR CT SPECT PET
Scan time 15-25 min 30-45 min 10 min 2 hours 1 h1/ 2-2 hours
Radiation None None 1.5-2 mSv (64-slice Coronary CT) 41 mSv (Thallium stress/rest)
9 mSv (Sestamibi)
14 mSv (F-18 FDG)
6–10 mSv (multi-detector row CT)
1–1.3 mSv
1.5-6 mSv (multi-detector coronary
calcium scoring) [124]
Risks None NSF (related to some types of
gadolinium-based contrast if
severe renal failure)
Radiation Renal failure Allergy Radiation Allergy (rare) Radiation Allergy (rare)
Contra-indications None MRI-incompatible implants and
devices Pregnancy during first
trimester (precautionary)
Renal failure Pregnancy Pregnancy Pregnancy
Limitations Operator dependent Acoustic
window (obese, COPD) Imaging




Not ideal for serial follow-up owing
to radiation Currently not suited for
detection of fibrosis, perfusion and
wall motion Blood flow cannot
be assessed
Availability Low spatial resolution Availability Low spatial
resolution
Accuracy of LV /RV function
and volumes
++ 3D echo +++ - ++ -
Wall thickness /Mass
quantification
+ (localised hypertrophy can be
missed)
+++ + - -
Detection of oedema - (non-specific findings such as
wall thickening)
+++ (STIR sequences) - + (non-specific; areas of reduced
perfusion)
+++ FDG (uptake)
Imaging of fibrosis - (suspected with 2D strain) +++ + - +
Detection of microvascular
disease/ Stress Perfusion




- + (Field of research, CMR
spectroscopy)





















Table 5 Summary of the main CMR findings in various NICMP
Cine STIR Stress Perfusion EGE LGE




Normal or hyposignal intensity
in the area of perfusion defect
Patchy or confluent in regions of
maximal wall thickening and LV/RV
insertion points
Amyloidosis Homogeneously thickened LV wall
Thickened RV wall, interatrial septum,
valves Pericardial effusion
Myocardial hypointensity Diffuse perfusion defect Diffuse perfusion defect Widespread circumferential (commonest)
Mid-wall Sub-epicardial Inter-atrial
septum RV wall
Anderson-Fabry Concentric hypertrophy Normal Not assessed with CMR Normal Mid-wall in basal inferolateral wall
Sub-epicardial (rarely)
DCM Dilated LV and/or RV Reduced LVEF Normal Normal Normal or hyposignal intensity
within the LV if thrombus
Mid-wall septal (commonest) Epicardial
Diffuse
ARVC Dilated RV
RV dysfunction - - RV free wall (difficult to image)
Focal aneurysms Mid-wall septal, inferolateral or inferior
Local hypo or akinesia
LV wall (ALVC)
Myocarditis Wall motion abnormalities Focal epicardial or
transmural hypersignal intensity
Not performed in the acute
setting




Tako-tsubo Mid and apical akinesia (ballooning) Focal, transient transmural Normal Normal Normal
Compensatory basal hyperkinesia hyper-intensity (apical segments)
Sarcoidosis Normal or Focal areas of
hypersignal intensity
- Focal Focal patchy, mid-wall or
sub-epicardial or subendocardial
Wall motion abnormalities or
thinning
Basal and mid-septum mostly
LV and/or RV dysfunction Sub-endocardium of RV side of the
septum and RV free wall
LVNC Hyper-trabeculation (non-compacted
over compacted > 2.3)
Normal Sub-endocardial perfusion
defects
Sub-endocardial lack of EGE Sub-endocardial, mid-wall or transmural
trabecular enhancement
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use a single piece of equipment for a combined assess-
ment of coronary anatomy, perfusion, function and me-
tabolism or coronary calcification. However, radiation
exposure as well as availability and cost remain an issue.
Table 4 summarises the diagnostic ability of various
imaging techniques extensively used in the work-up of a
newly diagnosed cardiomyopathy. Table 5 summarises
the main CMR findings of most frequent NICMP.
Future directions
CMR spectroscopy (MRS) and CMR-based molecular
imaging have appeared recently as non-invasive tools for
assessing myocardial metabolism using the intrinsic prop-
erties of nuclei including Phosporus-31, proton, sodium-
23, oxygen-17 and 13-carbon [135]. Phosphorus-31 is the
most widely used form of spectroscopy and allows detec-
tion of adenosine -5’ triphosphate (ATP) and phosphocrea-
tine (PCr), the high energy phosphate compounds of the
heart. This allows identification and quantification of
deranged cardiac energy metabolism in heart failure [136].
Thus, PCr: ATP ratios appeared reduced in heart failure
correlating with functional class and LVEF, but were also
reported as strong predictors of prognosis and long-term
survival [137]. Recently, absolute quantification of PCr and
ATP was achieved demonstrating a marked reduction of
these elements in heart failure associated with a reduced
rate of turnover of ATP, a sensitive parameter of metabolic
derangement. MRS holds promising perspectives to moni-
tor energetic changes linked to conventional or novel heart
failure treatments which improved PCr:ATP ratios to-
gether with clinical improvement [138]. Recently, Proton
MRS has been used to quantify myocardial triglyceride
content as an early marker of diabetic heart disease [139].
MRS offers new insights in the assessment of prognosis
and monitoring of therapeutic strategies in heart failure
but remains limited by low temporal and spatial resolution
and low reproducibility. Additionally, available studies are
still limited by their small sample size.
Newly developed quantitative Oxygen-sensitive CMR
techniques have been designed to directly evaluate myo-
cardial oxygen consumption [140]. Elevated deoxyhemo-
globin seen in a territory subtented by a stenotic coronary
artery can be assessed by blood oxygen level dependent
(BOLD) CMR. BOLD CMR relies on paramagnetic prop-
erties of deoxyhemoglobin leading to signal loss in T2
and T2*-weighted sequences thus acting as a natural con-
trast agent [141-145]. This method provides new insights
in the evaluation of myocardial blood flow (MBF), myo-
cardial blood volume (MBV), fractional oxygen extraction
(OEF) and myocardial oxygen consumption (MVO2)
[143]. MBF measured during stress showed the best
correlation with PET data in a canine model of severe
coronary artery stenosis [143]. Interestingly, KaramitsosConclusions
et al showed that regional myocardial perfusion and oxy-
genation were dissociated in a significant proportion of
segments in patients with coronary artery disease demon-
strating that reduced perfusion does not always lead to
deoxygenation whereas normal perfusion is usually asso-
ciated with normal oxygenation. Friedrich et al found
a significant correlation between BOLD T2* signal inten-
sity changes and thallium-SPECT in patients with coron-
ary artery disease [145]. These growing techniques offer
potential possible alternatives to nuclear techniques and
new insights into pathophysiology of diseases.
Through a wide range of sequences, CMR offers a
unique non-invasive tool which should be integral part
of the clinical work-up of a cardiomyopathy.
In vivo tissue characterisation remains a major strength
of CMR compared to other non-invasive techniques
detecting and distinguishing oedema from fat, fibrosis
and myocardial infiltration. Its excellent spatial resolution
set it above other imaging techniques to analyse RV
mophology and detect RV cardiomyopathies and for iden-
tification of regional ventricular hypertrophy or dilatation.
Although, CMR provides precious and irreplaceable
additional information to standard imaging and invasive
methods, it cannot be seen as an alternative to these
techniques yet and as a one stop shop but as a unique
supplementary method able to characterise abnormal
tissue in vivo, allowing pre-clinical detection of disease
process and novel parameters for risk stratification.
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